TIAA CREF Investment Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-253,489
| Closed | -$2.84M | – | 3103 |
|
|
2017
Q3 | $2.84M | Sell |
253,489
-4,762
| -2% | -$52.5K | ﹤0.01% | 1962 |
|
|
2017
Q2 | $2.84M | Sell |
258,251
-3,261
| -1% | -$32.6K | ﹤0.01% | 1961 |
|
|
2017
Q1 | $2.56M | Buy |
261,512
+38,834
| +17% | +$388K | ﹤0.01% | 1988 |
|
|
2016
Q4 | $2.4M | Buy |
222,678
+25,428
| +13% | +$254K | ﹤0.01% | 2081 |
|
|
2016
Q3 | $2.02K | Sell |
197,250
-510
| -0.3% | -$5.55K | ﹤0.01% | 2165 |
|
|
2016
Q2 | $2.58M | Buy |
197,760
+36,451
| +23% | +$478K | ﹤0.01% | 1966 |
|
|
2016
Q1 | $1.77M | Sell |
161,309
-7,620
| -5% | -$67.8K | ﹤0.01% | 2142 |
|
|
2015
Q4 | $1.55M | Hold |
168,929
| – | – | ﹤0.01% | 2314 |
|
|
2015
Q3 | $1.17M | Sell |
168,929
-9,495
| -5% | -$81.3K | ﹤0.01% | 2473 |
|
|
2015
Q2 | $1.75M | Sell |
178,424
-16,878
| -9% | -$154K | ﹤0.01% | 2385 |
|
|
2015
Q1 | $1.73M | Sell |
195,302
-5,143
| -3% | -$41K | ﹤0.01% | 2312 |
|
|
2014
Q4 | $1.76M | Sell |
200,445
-12,209
| -6% | -$98.8K | ﹤0.01% | 2336 |
|
|
2014
Q3 | $1.47M | Sell |
212,654
-5,732
| -3% | -$34.3K | ﹤0.01% | 2421 |
|
|
2014
Q2 | $1.15M | Sell |
218,386
-45,551
| -17% | -$222K | ﹤0.01% | 2641 |
|
|
2014
Q1 | $1.2M | Sell |
263,937
-40,196
| -13% | -$194K | ﹤0.01% | 2539 |
|
|
2013
Q4 | $1.53M | Sell |
304,133
-40,638
| -12% | -$196K | ﹤0.01% | 2405 |
|
|
2013
Q3 | $1.75M | Sell |
344,771
-2,488
| -0.7% | -$13.9K | ﹤0.01% | 2297 |
|
|
2013
Q2 | $1.72M | Buy |
+347,259
| New | +$1.65M | ﹤0.01% | 2261 |
|
TIAA CREF Investment Management's SCLN Position: Q4 2017 in Review
TIAA CREF Investment Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 253,489 shares — an estimated $2.84M sold.
TIAA CREF Investment Management first reported a position in SCLN in Q2 2013 and held it in 18 quarters. The position peaked at $2.84M in Q2 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- TIAA CREF Investment Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- TIAA CREF Investment Management sold 253,489 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $2.84M.
- TIAA CREF Investment Management first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 18 quarters.
- TIAA CREF Investment Management's Sciclone Pharmaceuticals Inc position peaked at $2.84M in Q2 2017.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on TIAA CREF Investment Management's 13F filing for Q4 2017, filed 14 Feb 2018.